Acuitas Therapeutics

Headquarters

6190 Agronomy Road, Suite 405 Vancouver, BC, V6T 1Z3

Email: info@acuitastx.com
Facebook: @Acuitas
Twitter: @Acuitastx
linkedin.com/acuitastx
Acuitas: (noun) insight, perception, sharpness.

NEWS ALERT

  • Jul. 1, 2020 – Click to see a news release regarding our partner, BioNTech, and their clinical trial data for a COVID-19 vaccine. Our proprietary lipid nanoparticles are an important aspect of BioNTech’s mRNA vaccine. Link

PUBLICATION ALERT

  • Jun. 30, 2020 – Collaboration with Dr. Nachbagauer in the development of a universal influenza virus vaccine (Mol Ther 2020). Link
  • Jun. 30, 2020 – Collaboration with Dr. Kurtis in the development of a vaccine based on PfGARP that partially protects subjects against malaria challenge (Nature 2020). Link

VIDEO ALERT

  • Jun. 9, 2020 – Click to see a short video on how the Acuitas Therapeutics’ lipid nanoparticle triggers uptake into a cell. Link

PUBLICATION ALERT

  • Mar. 30, 2020 – Our President and CEO, Dr. Thomas Madden, has been inducted into the very prestigious American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. Link
  • Jan. 30, 2020 – Collaboration with Dr. Muzykantov in the development of mRNA-LNP targeting cerebral Vasculature (Proc Natl Acad Sci U S A. 2020). Link
  • Jan. 30, 2020 – Collaboration with Dr. Hensley in the development of mRNA-LNP vaccine for infants (Sci Transl Med. 2020). Link
  • Sep. 20, 2019 – Collaboration with Dr. Sanders in the delivery of self-amplifying mRNA with LNPs (Mol Ther Nucleic Acids 2019). Link
  • Apr. 12, 2019 – Collaboration with Dr. Weissman in the development of mRNA-LNP for HIV vaccine (Mol Ther Nucleic Acids 2019). Link
  • Apr. 12, 2019 – Collaboration with Dr. Lee and colleagues in the development of ZFN mRNA-LNP for in vivo genome editing (Mol Ther 2019). Link
  • Nov. 22, 2018 – Collaboration with Dr. Muzykantov in the development of targeting mRNA-LNP (J Control Release 2018 Dec 10;291:106-115). Link
  • Aug. 22, 2018 – Collaboration with Dr. Weissman in the development of broadly protective/universal influenza virus vaccine using mRNA-LNP (Nat Commun. 2018 Aug. 22; 9(1): 3361). Link